University of Gothenburg
  2. About
  3. Find staff
  4. Mattias Lorentzon

Mattias Lorentzon

Professor/ Chief Physician

Department of Internal Medicine and Clinical Nutrition
Telephone
+46 31-343 19 79
Mail
mattias.lorentzon@medic.gu.se
Visiting address
Geriatriken
Mölndal
Postal address
Su sahlgrenska
41345 Göteborg

About Mattias Lorentzon

About Mattias Lorentzon

Mattias Lorentzon is a professor of geriatric medicine at the Institute of Medicine, University of Gothenburg, and serves as Chief Physician at the Osteoporosis Clinic at Sahlgrenska University Hospital in Mölndal. He is the founder and leader of the Fracture Liaison Service at Sahlgrenska University Hospital in Gothenburg. Currently, he heads the Clinical Osteoporosis Research Group at the Sahlgrenska Osteoporosis Centre, University of Gothenburg. Lorentzon acts as an expert reviewer for various international organizations and holds positions on the Scientific Advisory Council of the International Society for Clinical Densitometry and the Committee of Scientific Advisors for the International Osteoporosis Foundation.

He has received multiple international research accolades, including the 2024 European Calcified Tissue Society (ECTS) Steven Boonen Clinical Research Award. During his tenure as President of the Swedish Osteoporosis Society (2011-2015) and as an expert reviewer shaping diagnosis and treatment guidelines for the National Board of Health and Welfare (Socialstyrelsen), he significantly influenced the advancement of osteoporosis evaluation and treatment standards in Sweden. Lorentzon is a frequently sought-after reviewer for various scientific journals, such as NEJM, JBMR, JCEM, Osteoporosis International, and Annals of Internal Medicine. Additionally, he serves as a member of the editorial board of Osteoporosis International.

Research Interests and Publications

Lorentzon's primary research interests encompass osteoporosis and fracture epidemiology, fracture risk prediction, innovative assessments of bone strength, and the impact of gut microbiota on bone health. He has led and completed numerous Randomized Controlled Trials (RCTs) examining the effects of probiotic supplements. As the principal investigator of the large prospective SUPERB cohort study in Sweden, he aims to identify novel factors for osteoporosis and fracture prediction in elderly women. Lorentzon has made a substantial contribution in the testing of clinical efficacy of the highly effective and recently approved osteoporosis drug, romosozumab, as the principal investigator in Sweden. He currently leads several intervention studies in Gothenburg and Melbourne, exploring the effects of both 1st and 2nd generation probiotics on bone health. Lorentzon is an active member of the FRAX research team, a leading international osteoporosis epidemiology group focused on developing fracture prediction models.

His substantial contributions to osteoporosis research are reflected in over 320 peer-reviewed publications, including significant works in prestigious journals such as NEJM, JAMA, Nature, Nature Genetics, and The Lancet, garnering over 39,000 citations as of October 2024.

Selected publications

· Type 2 Diabetes and Fracture Risk in Older Women. Zoulakis M, Johansson L, Litsne H, Axelsson K, Lorentzon M. JAMA Netw Open. 2024 Aug 1;7(8):e2425106.

· Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial. Gregori G, Pivodic A, Magnusson P, Johansson L, Hjertonsson U, Brättemark E, Lorentzon M. JAMA Netw Open. 2024 Jun 3;7(6):e2415455.

· Khan MT, Dwibedi C, Sundh D, Pradhan M, Kraft JD, Caesar R, Tremaroli V*, Lorentzon M*, Bäckhed F*. Synergy and oxygen adaptation for development of next-generation probiotics. Nature. 2023 Aug;620(7973):381-385. doi: 10.1038/s41586-023-06378-w. *These authors jointly supervised this work.

· Risk of fracture in adults with type 2 diabetes in Sweden: A national cohort study. Axelsson KF, Litsne H, Kousoula K, Franzen S, Eliasson B, Lorentzon M. PLoS Med 2023;20(1):e1004172. DOI: 10.1371/journal.pmed.1004172.

· Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H, Lorentzon M. JAMA Netw Open. 2022 Jun 1;5(6):e2215396. doi: 10.1001/jamanetworkopen. 2022.15396.

· Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in four Swedish hospitals A Cohort Study. Axelsson KF, Johansson H, Lundh D, Möller M, Lorentzon M. J Bone Miner Res. 2020 Feb 25. doi: 10.1002/jbmr.3990

· Grade 1 Vertebral Fractures Identified by Densitometric Lateral Spine Imaging Predict Incident Major Osteoporotic Fracture Independently of Clinical Risk Factors and Bone Mineral Density in Older Women. Johansson L, Sundh D, Magnusson P, Rukmangatharajan K, Mellström D, Nilsson AG, Lorentzon M. J Bone Miner Res. 2020 Jun 15. doi: 10.1002/jbmr.4108

· Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. N Engl J Med. 2017 Sep 11. doi: 10.1056/NEJMoa1708322.

· Lactobacillus reuteri reduces bone loss in older women with low bone mineral density - a randomized, placebo-controlled, double-blind, clinical trial. Nilsson AG, Sundh D, Bäckhed F, Lorentzon M. J Intern Med. 2018 Jun 21. doi: 10.1111/joim.12805.

· Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M. JAMA. 2017 Jul 11;318(2):146-155. doi: 10.1001/jama.2017.8040.